Foram Parekh's questions to Dr Reddy's Laboratories Ltd (RDY) leadership • Q1 2026
Question
Foram Parekh from Bank of Baroda asked about the EBITDA margin for the NRT business, the growth outlook for the European business excluding NRT, and the potential size of the obesity market in India post-semaglutide launch.
Answer
CEO Erez Israeli confirmed that the EBITDA margin for the NRT business is expected to be around 25%. He projected the European business to deliver double-digit growth, which will accelerate with biosimilar launches. While he declined to quantify the Indian obesity market, he stated the unmet need is very clear and the opportunity is significant.